Health ยท Pan-African
African and European Regulators Issue Joint Guidelines to Speed Bundibugyo Ebola Vaccine Trials
The African Medicines Agency and the European Medicines Agency have issued joint guidelines to accelerate the development and clinical testing of vaccines against the Bundibugyo virus, which causes a form of Ebola disease. The available information gives no further detail on the guidelines' contents.
The African Medicines Agency (AMA) and the European Medicines Agency (EMA) have jointly issued guidelines intended to speed up the development and clinical testing of vaccines against the Bundibugyo virus (BDBV).
The virus causes a form of Ebola disease. According to the information available, the guidelines are aimed at accelerating how candidate vaccines are developed and evaluated in clinical trials.
The move brings together the regulatory bodies of Africa and Europe on a shared framework for work on BDBV vaccines. The available information does not set out the specific provisions of the guidelines, the date they take effect, which vaccine candidates they may apply to, or how trial sponsors and national authorities are expected to use them.
This account is therefore limited to the issuing of the guidelines and their stated purpose. Further detail from the two agencies would be needed to explain what the guidance requires and how it could affect the pace of vaccine trials.